(Q42424839)

31 October 2017

Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer (English)

1 reference

31 October 2017

1 reference

F Di Fiore

1

1 reference

31 October 2017

F Charbonnier

2

1 reference

31 October 2017

B Lefebure

3

1 reference

31 October 2017

M Laurent

4

1 reference

31 October 2017

F Le Pessot

5

1 reference

31 October 2017

P Michel

6

1 reference

31 October 2017

T Frebourg

7

1 reference

31 October 2017

language of work or name

English

0 references

publication date

1 July 2008

1 reference

British Journal of Cancer

31 October 2017

1 reference

31 October 2017

99

1 reference

31 October 2017

3

1 reference

31 October 2017

551-552

1 reference

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

31 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527802

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527802

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527802

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527802

Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527802

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527802

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527802

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527802

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

16 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18594536

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/SJ.BJC.6604451

1 reference

31 October 2017

1 reference

31 October 2017

PubMed publication ID

18594536

1 reference